Preclinical disposition and pharmacokinetics of volitinib, a novel selective cMet inhibitor.

被引：7
|
作者：
Gu, Yi [1 ]
Sai, Yang [1 ]
Wang, Jian [1 ]
Xia, Sumei [1 ]
Wang, Guanglin [1 ]
Zhao, Yuansheng [1 ]
Zhang, Li [1 ]
Yang, Wenqing [1 ]
Dai, Guangxiu [1 ]
Zhang, Weihan [1 ]
Gong, Qisun [1 ]
Tian, Zhenping [1 ]
Su, Weiguo [1 ]
机构：
[1] Hutchison MediPharma Ltd, Shanghai, Peoples R China
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-3371
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3371
引用
收藏
页数：1
相关论文
共 50 条
  • [31] In Vitro Investigation, Pharmacokinetics, and Disposition of Imeglimin, a Novel Oral Antidiabetic Drug, in Preclinical Species and Humans
    Clemence, Chevalier
    Fouqueray, Pascale
    Sebastien, Bolze
    DRUG METABOLISM AND DISPOSITION, 2020, 48 (12) : 1330 - 1346
  • [32] The preclinical selectivity and activity of APS03118, a highly selective and potent next-generation RET inhibitor.
    Drilon, Alexander
    Zhong, Jun
    Lu, Ying
    Liu, Yongbo
    Wang, Hao
    Chen, Minchun
    Chen, Xiaohu
    Zhu, John
    Lu, Shun
    Subbiah, Vivek
    CANCER RESEARCH, 2022, 82 (12)
  • [33] In situ demonstration of selective inhibition of the osteoclast v-ATPase using a novel inhibitor.
    Dodds, RA
    Minehart, H
    James, LE
    Ahern, R
    Farina, C
    Gowen, M
    JOURNAL OF BONE AND MINERAL RESEARCH, 1997, 12 : T368 - T368
  • [34] Preclinical Pharmacokinetics and Efficacy Assessment of a Potent and Selective MEK Inhibitor, GDC-0623
    Choo, E.
    Belvin, M.
    Merchant, M.
    Chan, E.
    Hollingshead, P.
    Orr, C.
    Boggs, J.
    Plise, E.
    Robarge, K.
    Zak, M.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 155 - 155
  • [35] Pharmacokinetics (PK) of lonafarnib (L), a farnesyl protein transferase inhibitor.
    Zhu, Y
    Statkevich, P
    Cutler, DL
    Calzetta, A
    Curtis, D
    Batra, VK
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P59 - P59
  • [36] In vitro evaluation of apixaban, a novel, potent, selective and orally bioavailable factor Xa inhibitor.
    Luettgen, Joseph M.
    Bozarth, Tracy A.
    Bozarth, Jeffrey M.
    Barbera, Frank A.
    Lam, Patrick Y.
    Quan, Mimi L.
    Pinto, Donald J.
    Wexler, Ruth R.
    Rendina, Alan R.
    Knabb, Robert M.
    BLOOD, 2006, 108 (11) : 112B - 112B
  • [37] Effect of food on the pharmacokinetics of lonafarnib, a farnesyl protein transferase inhibitor.
    Zhu, Y
    Statkevich, P
    Cutler, DL
    Pember, L
    Curtis, D
    Batra, VK
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P82 - P82
  • [38] Preclinical Pharmacokinetics of PDE-310, a Novel PDE4 Inhibitor
    Song, Jin Sook
    Rho, Hyeong Jin
    Park, Jong Shik
    Kim, Min Sun
    Lee, Byung Hoi
    Seo, Jeong-won
    Jeon, Dong Ju
    Cheon, Hyae Gyeong
    Ahn, Sung Hoon
    Kwon, Kwang-il
    Bae, Myung Ae
    DRUG METABOLISM AND PHARMACOKINETICS, 2011, 26 (02) : 192 - 200
  • [39] Preclinical pharmacokinetics of myrcludex B, a novel entry inhibitor for the treatment of HBV infections
    Mier, W.
    Schieck, A.
    Meier, A.
    Mueller, T.
    Haberkorn, U.
    Urban, S.
    JOURNAL OF PEPTIDE SCIENCE, 2010, 16 : 133 - 133
  • [40] Preclinical pharmacokinetics and metabolism of T0902611, a novel inhibitor of human cytomegalovirus
    Wright, M
    Ye, Q
    Dimaio-Knych, H
    Stein, C
    Le, H
    Mayorga, V
    Powers, J
    CLINICAL INFECTIOUS DISEASES, 2001, 33 (07) : 1166 - 1166
12345